Differences

This shows you the differences between two versions of the page.

--- projects:workgroups:kb-wg [2015/12/02 21:38]
lee
+++ projects:workgroups:kb-wg [2017/06/02 21:18]
rkboyce
@@ Line 1: / Line 1: @@
-====== Knowledgebase (LAERTES) Workgroup ======
+====== Pharmacovigilance evidence investigation Workgroup (used to be Knowledge Base / LAERTES)  ======
 <WRAP box justify round>
-**Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first release of LAERTES is schedule for April 2015
+**Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first staging release of LAERTES occurred last year and is reported in https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3.
 **Project Lead:**  [[http://ohdsi.org/who-we-are/collaborators/richard-d-boyce-2/|Richard D. Boyce, PhD]]
-**Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/1045-2/|Patrick Ryan, PhD]]
+**Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/erica-voss/|Erica Voss, MPH]]
 **Members:**
-See [[kb-wg#internal|Members List]]
+See [[kb-wg#internal|Members List]] but note that active membership is completely voluntary and open.
 **Start Date:** 6/10/2014
@@ Line 17: / Line 17: @@
 **Repository:**  [[https://github.com/OHDSI/KnowledgeBase]]
-**WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|Knowledge Base WG Minutes]]
+**WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|WG Minutes]]
+**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172| WG Agendas]]
+**Publications:**
+Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M., Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. (Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative). Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/s13326-017-0115-3. Available at: https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176.
+E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics, Available online 16 December 2016, ISSN 1532-0464, http://dx.doi.org/10.1016/j.jbi.2016.12.005.
+Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/s40264-014-0189-0, PubMed PMID: 24985530. PMCID: PMC4134480. http://link.springer.com/article/10.1007%2Fs40264-014-0189-0
-**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172|Knowledge Base WG Agendas]]
 </WRAP>
@@ Line 25: / Line 36: @@
 ==== Meetings (Telecon Info) ====
-    Schedule: Every other Wednesday at 12 Eastern starting from January 14th 2015
+    Schedule:
-    Please join my meeting.
-    https://global.gotomeeting.com/join/530277469
-    Use your microphone and speakers (VoIP) - a headset is recommended.
-    Or, call in using your telephone:
-    United States: +1 (224) 501-3217
+    - All team call once per month on the 4th Wednesday of each month at 9-10 Eastern. NOTE: no call in June. Back on schedule starting 7/26/17
-    Sweden: +46 (0) 853 527 836
+    - Touch point call on the 2nd Wednesday of each month 9-10 Eastern starting on 7/12/17
-    Access Code: 530-277-469
-=== Discussions ===
-[[http://forums.ohdsi.org/t/laertes-api/128|Laertes API]]
-[[http://forums.ohdsi.org/t/laertes-update-of-the-pharmacovigilance-signals/173/1|update of the pharmacovigilance signals]]
+ Please join my meeting from your computer, tablet or smartphone.
+ https://global.gotomeeting.com/join/530277469
-[[http://forums.ohdsi.org/t/laertes-pre-load-queries-hoi-from-x-to-snomed-rxnorm-bd-to-cd/180|LAERTES: pre-load queries - hoi from X to snomed, rxnorm BD to CD]]
+You can also dial in using your phone.
+ United States: +1 (224) 501-3217
-[[http://forums.ohdsi.org/t/laertes-getting-the-pivot-correct-rolling-up-from-clinical-drug-to-ingredient/181|LAERTES: getting the pivot correct - ‘rolling up’ from clinical drug to ingredient]]
+ Access Code: 530-277-469
+ More phone numbers
+ Canada: +1 (647) 497-9350
+ France: +33 170 950 594
+ Netherlands: +31 207 941 377
+ Sweden: +46 853 527 836
+ Switzerland: +41 225 4599 78
+ United Kingdom: +44 330 221 0088
+=== Discussions ===
+Search for "LAERTES" on [[http://forums.ohdsi.org/]]
 === GitHub Issues ===
-{{ghissues OHDSI/KnowledgeBase state:open}}
+[[https://github.com/OHDSI/KnowledgeBase/issues]]
+=== Members List (add or delete your name if you see an omission or error) ===
+Richard D. Boyce, University of Pittsburgh, Pittsburgh, PA, rdb20@pitt.edu
-=== Members List ===
+Erica A. Voss, Janssen Research & Development, LLC, Titusville, NJ, EVoss3@its.jnj.com
-- Abraham G. Hartzema, PhD, University of Florida, Gainesville, FL
+Vojtech Huser, National Institutes of Health, Bethesda, MD, vojtech.huser@nih.gov
-- Christian Reich, MD, PhD, AstraZeneca, Waltham MA
+Lee Evans, LTS Computing LLC, West Chester, PA, levans@ltscomputingllc.com
-- Christophe Lambert, PhD, University of New Mexico, Albuquerque, NM
+Christian Reich, QuintilesIMS, Burlington MA, reich@ohdsi.org
-- Erica A. Voss, MPH, Janssen Research and Development, Titusville, PA
+Jon D. Duke, Georgia Tech Research Institute, Atlanta, GA, Jon.Duke@gatech.edu
-- Gianluca Trifirò, PhD, University of Messina, Messina, Italy & Erasmus University Medical Center, Rotterdam, Netherlands
+Nicholas P. Tatonetti, Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University, New York, NY, nick.tatonetti@columbia.edu
-- J. Marc Overhage, MD, PhD, Siemens Healthcare, Malvern, PA
+Tal Lorberbaum, Columbia University, New York, NY, tal.lorberbaum@columbia.edu
-- Jon Duke, MD, Regenstrief Institute, Indianapolis IN
+Michel Dumontier, Stanford University, Stanford, CA, michel.dumontier@gmail.com
-- Johan Ellenius, PhD, Uppsala Monitoring Centre, Uppsala, Sweden
+Manfred Hauben, MD. MPH, Pfizer Inc, New York University Medical Center,  New York, NY, manfred.hauben@pfizer.com
-- Lee Evans, LTS Computing LLC, West Chester, PA
+Magnus Wallberg, Uppsala Monitoring Centre, Uppsala, Sweden, Magnus.Wallberg@who-umc.org
-- Majid Rastegar-Mojarad, MS, Mayo Clinic, Rochester, MN
+Lili Peng, AstraZeneca R&D, Boston , MA, Lili.Peng@astrazeneca.com
-- Mark Khayter, BS, Ephir, Boston, MA
+Sara Dempster, AstraZeneca R&D, Boston , MA, sara.dempster@astrazeneca.com
-- Martijn J. Schuemie, PhD, Janssen Research and Development, Titusville, PA
+Yongqun He, University of Michigan Medical School, Ann Arbor, Michigan, yongqunh@med.umich.edu
-- Michel Dumontier, PhD, Stanford University, Stanford, CA
+Anthony G. Sena, Janssen Research & Development, LLC, Titusville, NJ, asena5@its.jnj.com
-- Nicholas P. Tatonetti, PhD, Columbia University, New York, NY
+Vassilis Koutkias, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, vkoutkias@certh.gr
-- Niklas Noren, PhD, Uppsala Monitoring Centre, Uppsala, Sweden
+Pantelis Natsiavas, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, pnatsiavas@certh.gr
-- Rave Harpaz, PhD, Stanford University, Palo Alto, CA
+Patrick B. Ryan, Janssen Research & Development, LLC, Titusville, NJ, ryan@ohdsi.org
-- Vojtech Huser, MD PhD, National Institutes of Health, Bethesda, MD

Observational Health Data Sciences and Informatics

User Tools

Site Tools

Differences

Page Tools